News und Analysen

Regeneron Pharmaceuticals (NASDAQ: REGN) is a leader in the field of therapeutic proteins, with a history of more than 30 years of innovation and excellence. The biotech has partnered with Bayer to

Regeneron Pharmaceuticals (NASDAQ: REGN) is a leader in the field of therapeutic proteins, with a history of more than 30 years of innovation and excellence. The biotech has partnered with Bayer to

A new bull market is here ... almost. Some maintain that the S&P 500 has already begun a new bull market. Others, though, argue that the index must reach an all-time high first. Either way, many

A new bull market is here ... almost. Some maintain that the S&P 500 has already begun a new bull market. Others, though, argue that the index must reach an all-time high first. Either way, many

Over the past few years, several hot investing trends swept through Wall Street. First, it was the metaverse, and now it's artificial intelligence; there will likely be some new big thing in a year

Most people have either had cancer themselves or know someone who has. According to the American Cancer Society, 1 in 3 people in the U.S. will be diagnosed with one of the numerous forms of cancer.

Don't let anyone tell you that you must have a boatload of money to get started investing in stocks. It's simply not true. Sure, you'll need some upfront cash. However, even a modest amount is

Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer's Upjohn business. Down 29% since then, it has

Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer's Upjohn business. Down 29% since then, it has

Over the past few years, medical device companies have struggled as the pandemic disrupted much of the industry, and economic problems contributed to lower sales and increasing expenses. Healthcare

Novavax (NASDAQ: NVAX) has gone from a pandemic darling to a bust, with its shares falling by a whopping 83% over the past 12 months. The hope and optimism surrounding the stock has faded. Earlier

UnitedHealth Group (NYSE: UNH) has been a top healthcare stock to own for years. Today, it's among the largest healthcare companies in the world, worth $475 billion. Although it's a health insurer

UnitedHealth Group (NYSE: UNH) has been a top healthcare stock to own for years. Today, it's among the largest healthcare companies in the world, worth $475 billion. Although it's a health insurer

Being a buy-and-hold investor has advantages. For instance, it can be less stressful than day trading, and the combination of time and compounding is a powerful wealth generator. However, with

Being a buy-and-hold investor has advantages. For instance, it can be less stressful than day trading, and the combination of time and compounding is a powerful wealth generator. However, with

Being a buy-and-hold investor has advantages. For instance, it can be less stressful than day trading, and the combination of time and compounding is a powerful wealth generator. However, with

Pharma giant AbbVie (NYSE: ABBV) performed poorly in the first part of the year, especially after it reported its first-quarter results. This was its first quarterly update following the loss of

Illumina's (NASDAQ: ILMN) stock is down by 15% this year so far, and it's no surprise why. With the new disclosure of a Securities and Exchange Commission (SEC) investigation into its bedraggled

Illumina's (NASDAQ: ILMN) stock is down by 15% this year so far, and it's no surprise why. With the new disclosure of a Securities and Exchange Commission (SEC) investigation into its bedraggled

Illumina's (NASDAQ: ILMN) stock is down by 15% this year so far, and it's no surprise why. With the new disclosure of a Securities and Exchange Commission (SEC) investigation into its bedraggled

Canada's Tilray Brands (NASDAQ: TLRY) is having a strong trading session today. Specifically, the consumer packaged goods and cannabis company's stock was up by 6.75% on heavy volume as of 1:31 p.m

Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss

Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss